The integration of bevacizumab improves tumor response and survival in patients with refractory cervical cancer treated with radical chemoradiotherapy

Hua Yang; Ying Zhang; Changhao Liu; Bin Feng; Jianjun Zhang; Yan Zhou; Yutian Yin; Jianping Li; Weiwei Li; Vincent Balaya; Mei Shi; Lina Zhao; Lichun Wei

doi:10.21037/atm-21-3521

The integration of bevacizumab improves tumor response and survival in patients with refractory cervical cancer treated with radical chemoradiotherapy

Ann Transl Med. 2021 Jul;9(14):1184. doi: 10.21037/atm-21-3521.

Authors

Hua Yang¹, Ying Zhang¹, Changhao Liu¹, Bin Feng¹, Jianjun Zhang², Yan Zhou¹, Yutian Yin¹, Jianping Li¹, Weiwei Li¹, Vincent Balaya³, Mei Shi¹, Lina Zhao¹, Lichun Wei¹

Affiliations

¹ Department of Radiation Oncology, First Affiliated Hospital of Air Force Medical University, Xi'an, China.
² Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, China.
³ Département Femme-Mère-Enfant, Service de Gynécologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Abstract

Background: Management of refractory cervical cancers (CC) is a debated question and rises dilemma in clinical practice. This study aimed to assess the safety and effectiveness of bevacizumab combined with concurrent chemoradiotherapy in the treatment of refractory CC.

Methods: A total of 129 patients with refractory CC who received radical concurrent chemoradiotherapy (CCRT) were included in this study. Among the patients, 64 received combination treatment with bevacizumab, while the 65 remaining patients did not receive bevacizumab. Treatment response was evaluated according to the Response Evaluation Criteria in Solid Tumorsversion1.1. The Cox proportional-hazards model was applied to determine prognostic factors associated with overall survival and the tumor response during treatment was analyzed for patients treated with bevacizumab.

Results: Bevacizumab was an independent prognostic factor (P=0.017). Therefore, we only analyzed 64 patients who received combination treatment with bevacizumab. In the 64 patients treated with bevacizumab, the 3-year OS, locoregional relapse-free survival, and distant metastasis-free survival rates were 87.2%, 98.1%, and 81%, respectively. Complete clinical response rates were 37.8% (17/45) for patients with neoadjuvant chemotherapy and chemoradiotherapy after neoadjuvant chemotherapy (NACT), complete clinical response rates were 62.5% (40/64), 73.3% (33/45) and 52.6% (10/19) before brachytherapy (BT), respectively for the entire cohort, patients with NACT and chemoradiotherapy and patients with chemoradiotherapy only. The 2-year OS rate was higher for patients who achieved a complete clinical response BT than for patients who did not, 94.6% vs. 73.2%, P=0.03. Among the 64 patients who received it, 28 (43.8%) experienced hematological toxicities of grade 3 or 4, and 3 (4.7%) experienced grade 3 gastrointestinal toxicities.

Conclusions: Bevacizumab combined with radical chemoradiotherapy is a safe and tolerable treatment option for refractory CC, with quicker tumor regression and high OS, locoregional relapse-free survival, and distant metastasis-free survival rates.

Keywords: bevacizumab; chemoradiotherapy; refractory cervical cancer.